by Barry101 | Nov 27, 2024 | Press Release
Independent Board Members to Receive 100% of Director Compensation in AIM Stock Follows Previously Disclosed Amendments to Executive Employment Agreements to Reduce Cash Component of Compensation for CEO and COO Board and Management are Deeply Aligned with All AIM...
by Barry101 | Nov 25, 2024 | Press Release
Highlights How Positive Data in AIM’s Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic Cancer Warns Shareholders of Its Belief that the Activist Group and...
by Barry101 | Nov 19, 2024 | Press Release
OCALA, Fla., Nov. 19, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study evaluating AIM ImmunoTech’s...
by Barry101 | Nov 15, 2024 | Press Release
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma...
by Barry101 | Nov 6, 2024 | Press Release
OCALA, Fla., Nov. 06, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2024 operational and financial...
